Childhood brain stem neoplasm

Summary

Childhood brain stem neoplasm (MONDO:0002914) is a cancer and 5 clinical trials. Top therapeutic interventions include entinostat, nimotuzumab, and cixutumumab. A subtype of brainstem cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	childhood brain stem neoplasm
Mondo ID	MONDO:0002914
DOID	DOID:4206
NCIT	C5969
UMLS	C1332951
MedGen	272459
GARD	0027625
Is cancer (heuristic)	yes

Also known as: brain stem neoplasm · brainstem cancer of childhood · childhood brain stem neoplasm · childhood brain stem tumor · childhood brain stem tumour · childhood brainstem cancer · childhood brainstem neoplasm · childhood brainstem tumor · childhood brainstem tumour · childhood neoplasm of brain stem · childhood neoplasm of brainstem · childhood neoplasm of the brain stem · childhood neoplasm of the brainstem · childhood tumor of brain stem · childhood tumor of brainstem · childhood tumor of the brain stem · childhood tumor of the brainstem · childhood tumour of brain stem · childhood tumour of brainstem · childhood tumour of the brain stem (+27 more)

Disease family

An umbrella term covering 1 Mondo subtype.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › nervous system cancer › central nervous system cancer › brain cancer › infratentorial cancer › brainstem cancer › childhood brain stem neoplasm

Related subtypes (1): brain stem glioma

Subtypes (1): childhood brain stem glioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	3
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02672241	PHASE2	UNKNOWN	Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children
NCT06357377	PHASE1	NOT_YET_RECRUITING	A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors
NCT01182883	PHASE1	WITHDRAWN	A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT02780804	PHASE1	COMPLETED	Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
NCT04028479	Not specified	COMPLETED	The Registry of Oncology Outcomes Associated With Testing and Treatment

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ENTINOSTAT	3	1
NIMOTUZUMAB	3	1
CIXUTUMUMAB	2	1
PERILLYL ALCOHOL	2	1